Target
Audience
Hematologists, medical oncologists, and other healthcare personnel who care for and manage patients with multiple myeloma
Activity Overview
This Webcast provides an overview of the current and future treatment strategies for the following scenarios: 1) induction therapy for the patient who is transplant eligible; 2) induction for transplant ineligible patients; 3) relapsed or refractory disease; 3) maintenance of remission. There is also a discussion of future directions for patients with multiple myeloma. The myeloma experts at M. D. Anderson Cancer Center have each taken a topic in myeloma management and expounded on treatment variables, obstacles and evidence-based strategies utilized at their center. Dr Alexanian is the moderator, and Drs Giralt, Orlowski, and Weber present their thoughts and recommendations.
Educational
Objectives
After completing this activity, the participant will be able to:
- Discuss recent clinical trial results pertinent to the front-line treatment of multiple myeloma and apply this knowledge to decision making in patient management
- Explain which strategies for managing relapsed or refractory multiple myeloma are evidence-based and recommended by experts
- Clarify who is transplant eligible and how disease management strategies might affect stem cell collection or bone marrow collection
- Describe how to integrate new developments in myeloma research into daily clinical practice
- Review potential practice changing data and their implications for future patient management
- Discuss the current rationale regarding transplant options and the role of maintenance therapy
Disclosure
Statement
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
Raymond Alexanian, MD
University of Texas M. D. Anderson Cancer Center
Houston, TX
Disclosure with supporter: Speaker’s bureau for Celgene Corporation.
Additional disclosures: Speaker’s bureau for Millennium Pharmaceuticals, Inc.
Sergio Giralt, MD
University of Texas M. D. Anderson Cancer Center
Houston, TX
Disclosure with supporter: Speaker’s bureau for Celgene Corporation.
Additional disclosures: Speaker’s bureau for Millennium Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation.
Robert Orlowski, MD
University of Texas M. D. Anderson Cancer Center
Houston, TX
Disclosure with supporter: Consultant for Celgene Corporation.
Additional disclosures: Consultant for Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Ortho Biotech Products, L. P.; and Proteolix, Inc.
Donna Weber, MD
University of Texas M. D. Anderson Cancer Center
Houston, TX
Disclosure with supporter: Speaker’s bureau for and research funding from Celgene Corporation.
Additional disclosures: Speaker’s bureau for and research funding from Millennium Pharmaceuticals, Inc. Consultant for and research funding from MERCK & CO., Inc.
All materials are included with the permission of the authors.
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen
Kenneth Richardson, MD, Bradley Bongiovanni, ND, and Becky Lynch, RN, own stock options for AmerisourceBergen.
Sponsorship Statement
This activity is sponsored by Imedex, LLC.
Accreditation Statement
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.0 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
Unapproved and Investigational Uses of Drug and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this activity are the opinions of the authors and do not necessarily reflect the opinions of Imedex, LLC.
Support
This activity is supported by an unrestricted educational grant from Celgene Corporation.
|
